Bump. I’m going to do an analysis on the newly published CLBP phase II trial to be published in spine this month. Lots of positives but one of the negatives was the 23% drop out rate in the equivalent experimental group to the phase iii trial. Hopefully, they managed to get measures from the dropouts so they can do a comparative analysis to show the effect on the outcome. Hopefully. It is standard practice to do this but sometimes patients refuse to cooperate obviously.
Phase III chronic lower back pain primary end point, page-6
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |